SynthesisEuropean journal of clinical pharmacology2021
Ivy leaf (Hedera helix) for acute upper respiratory tract infections: an updated systematic review.
Synthesis in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Ivy leaves extract EA 575 in the treatment of cough during acute respiratory tract infections: meta-analysis of double-blind, randomized, placebo-controlled trials.Scientific reports · 2022Pooled it
- Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms.Journal of Korean medical science · 2026Trial
- From Traditional Remedy to Evidence-Based Phytotherapeutic Agent:Plants (Basel, Switzerland) · 2026Review
- Efficacy and Safety of Ivy Leaf Dry Extract EA 575 in Cough Management: An Updated Review of Clinical Evidence.Planta medica · 2026Review
- Herbal preparations traditionally used in upper respiratory tract infections: UHPLC-DAD-ESI-MS/MSBMC complementary medicine and therapies · 2026Article
- Immunomodulating effects of herbal cough medication - in vitro screening in a TLR7- and TLR8-mediated inflammatory model.BMC complementary medicine and therapies · 2026Article
- Antiparasitic Activity ofVeterinary sciences · 2026Article
- Comprehensive Identification and Abscisic Acid-Responsive Expression Profiling of NAC Transcription Factor in Triterpenoid Saponin inBiomolecules · 2025Article
- Efficacy and Safety of YJP-40 in Patients with Acute Bronchitis: A Randomized, Double-Blind, Parallel Group Study.Tuberculosis and respiratory diseases · 2025Article
- Ivy Leaf Dry Extract EA 575Pharmaceutics · 2025Article
- CYP2C8-Mediated Drug-Drug Interactions and the Factors Influencing the Interaction Magnitude.Drug design, development and therapy · 2025Review
- Effects of a powder made from three medicinal plants on growth performance, intestinal health, antioxidant activity, and anti-inflammatory ability in Xianghuang chickens.Frontiers in veterinary science · 2025Article
- Phytochemical and Bioactivity Studies onAntioxidants (Basel, Switzerland) · 2023Article
- Over-the-counter cough and cold medicines: reported poisonings of children before and after the 2012 and 2020 labelling changes in Australia.The Medical journal of Australia · 2023Article
- Natural Products for the Prevention and Treatment of Common Cold and Viral Respiratory Infections.Pharmaceuticals (Basel, Switzerland) · 2023Review
- [Chronic cough].Innere Medizin (Heidelberg, Germany) · 2023Review
- Therapeutic principles and unmet needs in the treatment of cough in pediatric patients: review and expert survey.BMC pediatrics · 2023Article
- Review
- Effect of the Administration of a Nutraceutical Supplement in Racehorses with Lower Airway Inflammation.Animals : an open access journal from MDPI · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcute cough due to viral upper respiratory tract infections (URTIs) and bronchitis is a common reason for patients to seek medical care. Non-antibiotic over-the-counter cough medications such as ivy leaf extract are frequently used but their efficacy is uncertain. Our purpose was to update our previous systematic review and evaluate the effectiveness and tolerability of ivy leaf in the treatment of acute URTIs in adult and pediatric populations.
methodsWe searched MEDLINE, EMBASE, the Cochrane Library, and clinical trial registries from December 2009 to January 2020. Randomized controlled trials (RCTs), controlled clinical trials (CCTs), and observational studies (OSs) investigating ivy leaf mono- or combination preparations were included. Two independent reviewers assessed records for eligibility and risk of bias and performed data extraction.
resultsSix RCTs, 1 CCT, and 4 OSs were identified. Since the publication of our previous review, the number of RCTs has increased. All studies concluded that ivy leaf extract is an effective and safe option for the treatment of cough due to URTIs and bronchitis. Three RCTs reported a more rapid reduction in cough severity and/or frequency under ivy leaf treatment. The clinical significance of these effects appears to be minimal. No serious adverse effects were reported. The overall quality of reporting was low and the risk of bias was high.
conclusionsIvy leaf preparations are safe for use in cough due to acute URTIs and bronchitis. However, effects are minimal at best and of uncertain clinical importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.